Showing posts with label players. Show all posts
Showing posts with label players. Show all posts

Sunday, 16 April 2017

Vaccine Partnering During The Forecast Period 2017 - 2020: Global Deal Trends, Players And Financials

Researchmoz added Most up-to-date research on "Vaccine Partnering During The Forecast Period 2017 - 2020: Global Deal Trends, Players And Financials" to its huge collection of research reports.

The Global Vaccine Partnering 2010-2015 report provides comprehensive understanding and unprecedented access to the vaccine partnering deals and agreements entered into by the worlds leading healthcare companies.
  • Trends in vaccine and adjuvant partnering deals
  • Deal terms analysis
  • Partnering agreement structure
  • Partnering contract documents
  • Top deals by value
  • Most active dealmakers
  • Average deal terms for vaccines
This report contains a comprehensive listing of all vaccine partnering deals announced since January 2009, including financial terms where available, including over 1,000 links to online deal records of actual vaccine partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.
The report takes readers through the vaccine deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering vaccine partnering deals.
The report presents average financial deal terms values for vaccine deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.
The middle section of the report explores the leaders in the vaccine partnering field; both the leading deal values and leading players are reported allowing readers to see who is succeeding in this growing market. This chapter also looks at the contributions by the big pharma and big biotech companies of the world in terms of deals made.

To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=487855

One of the key highlights of the report is that over 800 online deals records of actual vaccine deals as disclosed by the deal parties are included towards the end of the report in a directory format that is easy to reference. Each deal links via Weblink to an online version and all these deals are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), specific therapy and technology focus. In addition the report includes actual contract documents where available as submitted to the Securities Exchange Commission by companies and their deal partners.

Executive Summary
 
Chapter 1 – Introduction
 
Chapter 2 – Trends in vaccine dealmaking

2.1. Introduction
2.2. Vaccine partnering over the years
2.3. Vaccine partnering by deal type
2.4. Vaccine partnering by industry sector
2.5. Vaccine partnering by stage of development
2.6. Vaccine partnering by disease type
2.7. Partnering by specific vaccine technology type
 
Chapter 3 – Average financial deal terms for vaccine partnering
3.1. Introduction
3.2. Disclosed financials terms for vaccine partnering
3.3 Vaccine partnering headline values
3.4 Vaccine upfront payments
3.5 Vaccine deals with milestone payments
3.6 Vaccine deals with royalty rates

Friday, 7 April 2017

Infectious Vaccines Partnering Terms And Agreements 2017 To 2021: Global Deal Trends, Players And Financials

ResearchMoz presents this most up-to-date research on "Infectious Vaccines Partnering Terms And Agreements 2017 To 2021: Global Deal Trends, Players And Financials".

The Global Infectious Vaccines Partnering Terms and Agreements 2010 to 2016: Deal trends, players and financials report provides a detailed understanding and analysis of how and why companies enter infectious vaccines partnering deals. The majority of deals are development stage whereby the licensee obtains a right or an option right to license the licensors vaccine technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. The report also includes adjuvant deals and alliances.

This report provides details of the latest infectious vaccines agreements announced in the healthcare sectors.

Understanding the flexibility of a prospective partners negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered contract documents provide this insight where press releases and databases do not.

The initial chapters of this report provide an orientation of Infectious Vaccines dealmaking and business activities.

Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Infectious Vaccines dealmaking since 2010, including details of average headline, upfront, milestone and royalty terms. Infectious Vaccines deals since 2010. Deals are listed by headline value, signed by big pharma, most active Infectious Vaccines dealmaking companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 3 provides a review of the leading Infectious Vaccines deals since 2010. Deals are listed by headline value, signed by big pharma, most active Infectious Vaccines dealmaking companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in Infectious Vaccines dealmaking with a brief summary followed by a comprehensive listing of Infectious Vaccines deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 5 provides a comprehensive and detailed review of Infectious Vaccines partnering deals signed and announced since Jan to 2010, where a contract document is available in the public domain. The chapter is organized by company A-Z, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.



Chapter 6 provides a comprehensive and detailed review of Infectious Vaccines partnering deals signed and announced since Jan to 2010. The chapter is organized by specific Infectious Vaccines technology type in focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided organized by Infectious Vaccines partnering company A-Z, deal type definitions and Infectious Vaccines partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. The report also includes numerous tables and figures that illustrate the trends and activities in Infectious Vaccines partnering and dealmaking since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Infectious Vaccines technologies and products.

Report scope


Global Infectious Vaccines Partnering Terms and Agreements 2010 to 2016: Deal trends, players and financials is intended to provide the reader with an in-depth understanding and access to infectious vaccines trends and structure of deals entered into by leading companies worldwide.Global Infectious Vaccines Partnering Terms and Agreements 2010 to 2016: Deal trends, players and financials includes:

Trends in infectious vaccines dealmaking in the biopharma industry since 2010
Analysis of infectious vaccines deal structure
Access to headline, upfront, milestone and royalty data
Access to over 600 infectious vaccines deal records
Identify the most active infectious vaccine dealmakers since 2010
The leading infectious vaccines deals by value since 2010
Includes adjuvant deals and alliances since 2010

In Global Infectious Vaccines Partnering Terms and Agreements 2010 to 2016: Deal trends, players and financials, the available deals are listed by:

Company A-Z
Headline value
Stage of development at signing
Deal component type
Specific infectious therapy target

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Global Infectious Vaccines Partnering Terms and Agreements 2010 to 2016: Deal trends, players and financials report provides comprehensive access to available deals and contract documents for over 500 infectious vaccines deals. Analyzing actual contract agreements allows assessment of the following:

What are the precise rights granted or optioned?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How aresalesand payments audited?
What is the deal term?
How are the key terms of the agreement defined?


To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=826606